PME FY26 results presentation

• FY26 Revenue: $261.7M, up 22.9%
• Underlying EBIT: $196.1M, up 24.4%
• Underlying NPAT: $144.7M, up 24.1%
• 10 new contracts signed, worth $407M
• Renewed 6 contracts with 5-year extensions

Pro Medicus Ltd (ASX:PME) announced its FY26 full-year results, highlighting significant growth across various metrics. The company reported a 22.9% increase in revenue to $261.7 million, with underlying EBIT rising by 24.4% to $196.1 million and underlying net profit after tax (NPAT) up 24.1% to $144.7 million. Pro Medicus also secured 10 new contracts worth a total of $407 million and renewed 6 contracts with 5-year extensions. Additionally, the company achieved a 91% cash conversion rate and saw its cash and other financial assets increase by 20% to $252 million. Pro Medicus continues to expand its market presence, particularly in North America, where revenue grew by 45.9% to $190.9 million.

FY26 Revenue: $261.7M, Underlying EBIT: $196.1M, Underlying NPAT: $144.7M

Pro Medicus expects continued growth in the upcoming financial year, driven by new contract wins and renewals, particularly in North America. The company is also focusing on expanding its AI capabilities and integrating AI into its core offerings.